Skip to main content
    I

    Ironwood Pharmaceuticals Inc (IRWD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $4.85
    +0.02 (+0.41%)

    Market Cap: $799.61M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ironwood Pharmaceuticals Inc (IRWD) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Ironwood Pharmaceuticals (IRWD) trades at 5.4x trailing earnings and 2.0x sales. Its P/S of 2.0x is below its 5-year median of 2.8x. Its forward P/E is 12.3x. The median P/E across 9 similar companies is 12.7x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 56.1% lower over the next year.

    MultipleValue
    P/E (trailing)5.4x
    Forward P/E12.3x
    Price to sales2.0x
    EV/EBITDA4.1x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 53.5% below 4.3x.

    MultipleCurrent5-year median10-year median
    P/S2.0x2.8x4.3x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 6 of the 10 year ends shown that have a P/E, its P/E ranged from 9.9x in 2021 to 303.4x in 2024.

    Year endPriceP/EP/SP/B
    2025$3.3714.7x1.9xN/A
    2024$4.43303.4x2.0xN/A
    2023$11.44N/A4.0xN/A
    2022$12.3912.8x4.9x3.5x
    2021$11.669.9x4.6x3.2x
    2020$11.3914.4x4.7x29.4x
    2019$13.3124.6x4.9xN/A
    2018$10.36N/A4.6xN/A
    2017$14.99N/A7.5x228.1x
    2016$15.29N/A8.2x34.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IRWD

    What is IRWD's forward P/E ratio?

    Ironwood Pharmaceuticals has a forward P/E ratio of 12.3x.

    Is IRWD stock overvalued?

    GNG's valuation label for IRWD is Undervalued. Its P/E of 5.4x compares with a median of 12.7x across 9 similar companies.

    What is IRWD's price to sales ratio?

    Ironwood Pharmaceuticals has a price to sales ratio of 2.0x.